Drug Trial Radar · NCT06784193
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
180
Planned (sponsor's estimate)
Start
Dec 16, 2024
Primary completion
May 30, 2027
Study completion Aug 30, 2027
Sponsor
- Lead sponsor
- Olema Oncology, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 20, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a first-in-human, open-label, multicenter phase 1 study to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of OP-3136, a lysine acetyltransferases 6A and 6B (KAT6A/B) inhibitor, as monotherapy and in combination with other anticancer agents in participants with advanced solid tumors. This study consists of 2 parts: a dose escalation part (Part 1) and dose expansion part (Part 2).
Conditions
- Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)
- Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Metastatic Breast Cancer
- Fulvestrant
- Palazestrant
Interventions
OP-3136Drug
Selective inhibitor of HAT enzymes KAT6A and KAT6B
FulvestrantDrug
Selective estrogen receptor degrader (SERD)
PalazestrantDrug
Complete estrogen receptor antagonist (CERAN)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with dose-limiting toxicities in the Dose Escalation ArmsTime frame: Up to 28 days
- Incidence of adverse events and laboratory abnormalitiesTime frame: Up to 26 months
Locations
25 sites in 6 countries. Site status is shown where the registry gives one.
Banner MD Anderson Cancer Center
Gilbert, Arizona · Recruiting
University of Colorado
Aurora, Colorado · Recruiting
Florida Cancer Specialists
Sarasota, Florida · Recruiting
University Medical Center - New Orleans
New Orleans, Louisiana · Terminated
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
START - Midwest
Grand Rapids, Michigan · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
The Ohio State University
Columbus, Ohio · Recruiting
SCRI Oncology Partners
Nashville, Tennessee · Recruiting
Tennessee Oncology
Nashville, Tennessee · Recruiting
START - San Antonio
San Antonio, Texas · Recruiting
START - Mountain Region
West Valley City, Utah · Recruiting
The Kinghorn Cancer Centre
Darlinghurst, New South Wales, Australia · Recruiting
Liverpool Hospital
Liverpool, New South Wales, Australia · Recruiting
Macquarie University Clinical Trials Unit
Macquarie, New South Wales, Australia · Recruiting
Cancer Research South Australia
Adelaide, South Australia, Australia · Recruiting
Institut De Cancerologie De L'ouest
Saint-Herblain, Loire-Atlantique, France · Recruiting
Hôpital Paris Saint-Joseph
Paris, Paris, France · Recruiting
Institut Gustave Roussy
Villejuif, Val-de-Marne, France · Recruiting
Queen Mary Hospital
Hong Kong, Hong Kong, Hong Kong · Recruiting
START Dublin
Dublin, Dublin, Ireland · Recruiting
START - Barcelona
Barcelona, Barcelona, Spain · Recruiting
Start - Fjd
Madrid, Madrid, Spain · Recruiting
START Madrid - CIOCC
Madrid, Madrid, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.